Incyte (INCY) Return on Equity ROE from the first quarter 2026 to first quarter 2025 and annually, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Incyte Corporation  (NASDAQ: INCY)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Incyte's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Incyte in the first quarter 2026?
Incyte Corporation achieved a return on average equity (ROE) of 29.2 % in its first quarter 2026, this is above INCY's average return on equity of -28.39%.
Incyte Corporations equity during the 12 months ending in the first quarter 2026 are valued at $4 billion

ROE has advanced compared to 29.15% in the fourth quarter 2025, due to net income growth.

Within the Medical Laboratories industry 4 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2025 from 114 to 412.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Equity Change 53.31 % 49.89 % 46.67 % 39.17 % -
Y / Y Net Income Change 91.73 % 48.74 % 298.45 % - -6.69 %
Net Income (TTM) in Millions 1,432 1,287 1,189 871 21
Return On Equity (TTM) 29.2 % 29.15 % 29.83 % 24.09 % 0.64 %
INCY's Total Ranking # 412 # 114 # 339 # 426 # 2062
Equity (TTM) in Millions 5,623 5,167 4,651 4,171 3,668
Seq. Equity Change 8.81 % 11.1 % 11.52 % 13.72 % 6.38 %
Seq. Net Income Change 1.35 % -29.44 % 4.73 % 156 % -21.37 %

Back to INCY Management Effectiveness >> INCY's 5 Years Annual ROE >> Compare INCY ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 5
Sector # 59
Overall # 412

Return On Equity Statistics
High Average Low
56.49 %
-28.39 %
-1640.46 %
(Sep 30 2016)   (Sep 30 2015)





INCY Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 5,167 3,448 5,190 4,370 3,770
Y / Y Equity Change 49.89 % -33.57 % 18.76 % 15.92 % 44.37 %
Net Income in Millions 1,287 33 598 341 949
Y / Y Net Income Change 3844.96 % -94.54 % 75.42 % -64.09 % -
Return On Equity 24.9 % 0.95 % 11.51 % 7.8 % 25.16 %

Back to INCY Management Effectiveness >> INCY's 5 Years Annual ROE >> Compare INCY ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 24.9 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
INCY's' Return on Equity at Yahoo Finance
INCY's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for INCY's Competitors
Subscribers only: Roe for Incyte's Suppliers
Subscribers only: Return On Equity for INCY's Customers




Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector ROE
Pulmatrix Inc   78.57 %
Earth Science Tech Inc   71.44 %
Idexx Laboratories Inc  70.87 %
Elite Pharmaceuticals Inc   68.60 %
Escalon Medical Corp   66.85 %
3m Company  65.54 %
Aurinia Pharmaceuticals Inc   64.48 %
Lifemd Inc   63.70 %
Zoetis Inc   61.63 %
Vaxart Inc   61.43 %
Dariohealth Corp   60.52 %
Nrc Health  57.25 %
Oramed Pharmaceuticals Inc  55.40 %
Innoviva Inc   47.59 %
Concentra Group Holdings Parent Inc   46.95 %
Liquidia Corporation  46.82 %
Agilent Technologies inc   44.45 %
Tenet Healthcare Corp  44.20 %
Theravance Biopharma inc   43.85 %
Gilead Sciences Inc   42.33 %
Transmedics Group Inc   41.92 %
Abeona Therapeutics Inc   41.40 %
Apellis Pharmaceuticals Inc   39.71 %
Adma Biologics Inc   38.97 %
Bristol myers Squibb Company  38.94 %
Acadia Pharmaceuticals Inc   35.65 %
Spero Therapeutics Inc   35.58 %
Illumina Inc   33.99 %
Dexcom Inc   33.83 %
Rafael Holdings Inc  31.93 %

Date modified: 2026-09-12T06:11:26+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.